Ask about this productRelated genes to: P2RX5 antibody
- Gene:
- P2RX5 NIH gene
- Name:
- purinergic receptor P2X 5
- Previous symbol:
- -
- Synonyms:
- P2X5, LRH-1
- Chromosome:
- 17p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-05-14
- Date modifiied:
- 2016-10-05
Related products to: P2RX5 antibody
Related articles to: P2RX5 antibody
- Purinergic P2X receptors () play key roles in neuroinflammatory processes through ATP-gated ion channel signaling. Dysregulation of receptor activity has been implicated in maternal immune activation, mitochondrial dysfunction, oxidative stress, and synaptic abnormalities associated with autism spectrum disorder (ASD). Despite increasing mechanistic evidence, the contribution of gene variants to ASD remains poorly understood. - Source: PubMed
Publication date: 2026/07/18
Ünsel-Bolat GülBolat Hilmi - : Genetic generalized epilepsies (GGE) often remit in childhood, yet a subset of adults remain pharmacoresistant with substantial morbidity. The genetic basis of adult pharmacoresistant GGE is poorly defined. This descriptive study used whole-genome sequencing (WGS) to identify recurrent coding variants and pathways associated with pharmacoresistant adult GGE. : WGS was performed in ten racially diverse adults (mean age 37.2 years; range 20-52) with electroencephalographically confirmed, pharmacoresistant GGE (mean onset 13.7 years). Analysis prioritized variants present in at least 80% of participants and which were either (i) missense variants predicted deleterious with ANNOVAR or (ii) loss-of-function variants predicted high-impact from snpEff. Pathway enrichment and overlap with a commercial clinical epilepsy gene panel were assessed. : Filtering identified 133 unique, deleterious coding variants across 69 genes shared by at least eight participants. Four genes (APOL4, KMT2C, SON, VDR) overlapped a clinical epilepsy panel, supporting the capacity of WGS to recover clinically relevant loci. Prioritized loci implicated gastrointestinal and metabolic regulators (e.g., MUC6, PNLIPRP2), chemosensory receptors (OR10D3, OR8U1, TAS2R19), neuroimmune mediators (LILRA2, SIGLEC12, OAS2), and ion transporters (KCNJ12, P2RX5, RHBG), consistent with multifactorial mechanisms of pharmacoresistance. : This exploratory WGS study focused exclusively on adults with pharmacoresistant GGE, revealing shared high-impact variants and convergent pathways spanning absorption/metabolism, vitamin D signaling, immunity, and ion transport. Findings broaden the genetic landscape of pharmacoresistant GGE while motivating validation in larger, multiethnic cohorts. - Source: PubMed
Publication date: 2026/05/14
Kidder Benjamin LXu JianGeng RuiDlugas HunterVavilikolanu AnushaChen WeiWasade Vibhangini S - This study aims to investigate the impact of P2RX5 on the clinical pathological characteristics and prognosis of endometrial carcinoma, and to explore its potential underlying mechanisms. - Source: PubMed
Publication date: 2026/03/15
Huang Li-YanSu Qun-YingLong Qin-QinTian Feng-QinZhu Xiao-YingLong Xi-Dai - Periodontitis is the leading cause of tooth loss, with alveolar bone resorption serving as its fundamental pathological feature. Identifying key regulatory genes and molecular mechanisms is essential for enhancing preventive and therapeutic strategies. Nevertheless, reliable biomarkers and comprehensive regulatory networks have yet to be elucidated. This study aims to systematically identify candidate alveolar bone resorption hub genes (ABRHUB) and their regulatory networks through bioinformatics analysis. Our objective is to establish a bioinformatics foundation for generating hypotheses about the mechanisms underlying periodontitis progression and to identify potential targets for future experimental validation. The GSE16134 dataset extracted from the GEO database was utilized to screen differentially expressed genes in patients with periodontitis and explore the significance of alveolar bone resorption in the prevention and treatment of this condition. Furthermore, these genes were intersected with modular genes screened by weighted gene co-expression network analysis (WGCNA) as well as osteoclast-related genes obtained from molecular characterization databases, and co-expression differential genes (co-DEGs) were obtained. The co-DEGs were subjected to in-depth analysis using various machine learning algorithms. The validation set GSE10334 and qRT-PCR analysis were utilized for double validation, ultimately confirming ABRHUB. The diagnostic value and immune relevance of ABRHUB were further evaluated, and the potential miRNAs and lncRNAs associated with these key genes were predicted using relevant databases. A significant correlation exists between alveolar bone resorption and periodontitis. Through differential analysis of multiple databases and the integration of machine learning techniques, we identified four key ABRHUB genes: NEDD9, P2RX5, CSF1R and NPR3. Subsequently, we validated these genes using the GSE10334 validation set and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses, and constructed diagnostic and risk models to elucidate the potential utility of ABRHUB in predicting alveolar bone resorption. Furthermore, the calibration curves we established further validated the accuracy of the model predictions. Ultimately, based on these ABRHUB genes, we constructed a lncRNA-miRNA-mRNA molecular regulatory network, providing a significant bioinformatics foundation for future studies. Four genes associated with osteoclast function, namely NEDD9, P2RX5, CSF1R and NPR3, may serve as potential candidate biomarkers for alveolar bone resorption. Notably, the down-regulation of miR-1260b, miR-1224-5p, miR-3156-5p and miR-4286 may contribute to the progression of periodontitis by promoting the expression of NEDD9, P2RX5 and CSF1R. - Source: PubMed
Publication date: 2026/04/16
Lv WeiweiZhang WanyanZheng MaolinWang XiaodanLin DongHu ShichenCai XingyuZhang MingLi ChenghuaWu Yan - While CD19- and BCMA-directed immunotherapies have improved outcomes for B-lymphoid and plasma cell malignancies, frequent relapses with antigen loss/downregulation highlight the need for new targets. Here, using transcriptomic datasets and newly-developed monoclonal antibodies, we show that , long considered a pseudogene in humans, encodes a stable protein in 80% of individuals of African descent carrying the ancestral haplotype. Like CD19, P2RX5 displays B-cell lineage-restricted expression in normal tissues. Unlike CD19, P2RX5 is expressed not only in B-cell neoplasms, but also in T-cell leukemia (T-ALL) and multiple myeloma (MM). We developed P2RX5-directed bispecific T-cell engagers and CAR T cells, which killed T-ALL cells with no evidence of T-cell fratricide. These agents were non-inferior to FDA-approved CD19- and BCMA-directed immunotherapeutics in cell culture and xenograft models of Burkitt lymphoma and MM, while maintaining potency against CD19- and BCMA-negative variants. Hence, P2RX5 is a unique multi-lineage target for frontline or salvage immunotherapy. - Source: PubMed
Publication date: 2026/01/26
Ang ZhiweiCastro AnnetteParuzzo LucaSchimdt CarolinHasanali Zainul SHayer Katharina EStella FedericoSoldan Samantha STorres-Diz ManuelKwok ChristopherSainos Patricia KingJi KaylaKrohl Patrick JFine JustynSehgal PriyankaMartinez DanielSpangler Jamie BRiley James LVogl Dan TPorazzi PatriziaPillai VinodhLieberman Paul MAllman DavidRuella MarcoThomas-Tikhonenko Andrei